TRIAZINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS
    1.
    发明申请
    TRIAZINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS 审中-公开
    三氮嗪11-β羟基类固醇脱氢酶I型抑制剂

    公开(公告)号:WO2007103694A2

    公开(公告)日:2007-09-13

    申请号:PCT/US2007063012

    申请日:2007-03-01

    CPC classification number: C07D253/10 C07D253/07

    Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 and R 3 are defined herein.

    Abstract translation: 提供了11-β-羟基类固醇脱氢酶I型抑制剂的新型化合物。 11-β-羟基类固醇脱氢酶I型抑制剂可用于治疗,预防或减缓需要11-β-羟基类固醇脱氢酶I型抑制剂治疗的疾病的进展。 这些新型化合物具有以下结构:(I)或其立体异构体或前药或药学上可接受的盐,其中R 1,R 2,R 3, 在此定义。

    THIENOPYRIMIDINONE DERIVATIVES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS
    5.
    发明申请
    THIENOPYRIMIDINONE DERIVATIVES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS 审中-公开
    作为MELANIN浓缩激素受体-1拮抗剂的三烯酰基嘧啶衍生物

    公开(公告)号:WO2007050726A3

    公开(公告)日:2007-08-30

    申请号:PCT/US2006041725

    申请日:2006-10-26

    CPC classification number: C07D495/04

    Abstract: The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.

    Abstract translation: 本申请提供化合物,包括根据式I的所有立体异构体,溶剂合物,前药和药学上可接受的形式。另外,本申请提供含有至少一种根据式I的化合物和任选的至少一种另外的治疗剂的药物组合物。 最后,本申请提供了通过施用治疗有效剂量的根据式I的化合物治疗患有MCHR-1调节的疾病或病症例如肥胖,糖尿病,抑郁或焦虑的患者的方法。

Patent Agency Ranking